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Summary The Expanded Newborn Screening Pro-
gram (MS/MS) in the region of Galicia (NW Spain)
was initiated in 2000 and includes the measurement of
methionine levels in dried blood spots. Between June
2000 and June 2007, 140 818 newborns were analysed,
and six cases of persistent hypermethioninaemia were
detected: one homocystinuria due to cystathionine
b-synthase (CbS) deficiency, and five methionine
adenosyltransferase I/III (MAT I/III) deficiencies.
The five cases of MAT I/III deficiency represent an
incidence of 1/28 163 newborns. In these five patients,
methionine levels in dried blood spots ranged from 50
to 147 mmol/L. At confirmation of the persistence of
the hypermethioninaemia in a subsequent plasma sam-
ple, plasma methionine concentrations were moderate-
ly elevated in 4 of the 5 patients (mean 256 mmol/L),
while total homocysteine (tHcy) was normal; the
remaining patient showed plasma methionine of
573 mmol/L and tHcy of 22.8 mmol/L. All five patients
were heterozygous for the same dominant mutation,
R264H in the MAT1A gene. With a diet not exceeding
recommended protein requirements for their age, all
patients maintainedmethionine levels below 300 mmol/L.
Currently, with a mean of 2.5 years since diagnosis,
the patients are asymptomatic and show developmen-
tal quotients within the normal range. Our results
show a rather high frequency of hypermethioninaemia
due to MAT I/III deficiency in the Galician neonatal
population, indicating a need for further studies to
evaluate the impact of persistent isolated hyperme-
thioninaemia in neonatal screening programmes.
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Introduction
Expanded neonatal screening programmes based on
analysis of dried blood spots by tandem mass spec-
trometry (MS/MS) habitually include methionine mea-
surement (Wilcken et al 2003). This permits diagnosis
of classic homocystinuria (cystathionine b-synthase
(CbS) deficiency) and hypermethioninaemia without
homocystinuria. In addition to situations of transitory
neonatal hypermethioninaemia, related to high methi-
onine intake, and once type I tyrosinaemia and severe
hepatic disease have been ruled out, isolated and per-
sistent cases of hypermethioninaemia can be detected
(Mudd et al 1995, 2001). With rare exceptions, this
disorder is due to a methionine adenosyltransferase
I/III (MAT I/III) deficiency.
MAT is the enzyme catalysing the synthesis of
S-adenosylmethionine (AdoMet) from methionine
and ATP. In mammals three forms of MAT have
been described: MAT I, MAT II and MAT III. MAT
II is encoded by theMAT2A gene, expressed mainly in
extrahepatic tissues, fetal liver and hepatocarcinoma.
MAT I and MAT III, expressed mainly in adult liver,
are a tetramer and a dimer, respectively, of the same
polypeptide chain, encoded by the MAT1A gene.
MAT I/III deficiency (OMIM 250850) is caused by
mutations in the MAT1A gene that abolish or reduce
the activity of this enzyme, leading to persistent
hypermethioninaemia, as noted above. It can show
either recessive or dominant autosomal inheritance
(Blom et al 1992; Chamberlin et al 1997; Mudd et al
1995; Nagao and Oyanagi 1997). Most affected indi-
viduals do not present clinical symptoms, but some of
those with the most severe losses of activity have
developed neurological problems (tremor, dystonia,
dysmetria, language difficulties or myelination disor-
ders) and/or reduced intelligence or developmental
quotients (Chamberlin et al 1996, 1997; Mudd et al
2000, 2001).
Cases of isolated persistent hypermethioninaemia
have been diagnosed previously in neonatal screening
programmes (Chien et al 2005; Kim et al 2002), but
assessment of the impact of this abnormality in the
population requires further studies. In our region,
Galicia, the expanded neonatal screening programme
using MS/MS was introduced in June 2000, and to date
140 818 newborns have been analysed. A total of 6
cases of persistent hypermethioninaemia have been
detected: one case of CbS deficiency and 5 cases of
MAT I/III deficiency (plus an additional case of MAT
I/III deficiency, a sister, diagnosed subsequently). The
patients with MAT I/III deficiency are all heterozy-
gous for the same dominant mutation in the MAT1A
gene. Here we report the diagnosis and follow-up of
these cases.
Patients and methods
Patients
The five children (3 male, 2 female) who have now
been diagnosed with MAT I/III deficiency were
identified in their neonatal periods in Galicia over
the last 7 years (between June 2000 and June 2007) in
the Galician Program for Early Detection of Metabolic
Alterations. The five children were all from Galician
families, from different locations in the region. All
have been monitored from diagnosis until the present
in the Metabolic Disorders Unit of the University
Clinical Hospital of Santiago de Compostela. All five
showed methionine levels above the cut-off level in
dried blood spots taken in the first few days of life (our
newborn screening programme recommends the third
day of life of the newborn). Quantitative analyses were
also performed of amino acids and total homocysteine
(tHcy) in plasma, and amino acids in urine. Once
hypermethioninaemia without homocystinuria had
been demonstrated (plasma tHcy normal or only
slightly elevated), analysis of the MAT1A gene was
performed.
Age, presence/absence of symptoms at diagnosis,
and methionine levels at diagnosis and at confirmation
were recorded for each case. Clinical course was
subsequently monitored, recording mean and range
of methionine level over time. The patients received a
diet that did not exceed the recommended protein
requirement for their age, permitting normal growth
and development. Possible correlations between psy-
chomotor development and methionine level were
investigated at diagnosis and subsequently.
Methods
Neonatal screening by MS/MS analysis of dried blood
spots in filter paper, obtained on the third day of life
of the newborn
A blood paper disc was eluted with a solution of
methanol containing internal standards of amino acids
and acylcarnitines labelled isotopically with [2H3]-
methionine (Cambridge Isotopes Laboratories, Inc.,
Andover, MA, USA). Derivatization to butyl esters
was achieved by addition of a solution of hydrogen
chloride in 1-butanol (Riedel-de Hae¨n, ref. 35072).
The residue was reconstituted with the mobile phase
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(acetonitrile–water 1:1, formic acid 0.05%). An aliquot
was injected into the mass spectrometer (Sciex API
2000). If the measured concentration exceeded the
99th centile for the study population, a second sample
was requested. For methionine, this value ranged
between 48 and 56 mmol/L over the study period.
Quantitative analysis of amino acids in samples
of plasma and urine
This was carried out by ion-exchange chromatography
(Biochrom 30 autoanalyser) after deproteinization of
the sample (plasma or urine) with 5-sulfosalicylic acid,
with post-column reaction with ninhydrin, and making
use of L-norleucine as internal standard. The concen-
tration of urinary amino acids is referred to creatinine
concentration. Amino acid levels were evaluated with
respect to reference ranges for the corresponding age
group.
Plasma tHcy
Plasma tHcy was determined by HPLC with fluoromet-
ric detection using a Hitachi apparatus and a specific
kit (Immundiagnostik AG, Bensheim, Germany).
The tHcy level was considered to be elevated at
concentrations above 15 mmol/L.
Molecular study
DNA was isolated from 300 ml blood samples using
the Puregene DNA isolation kit (Gentra Systems, Inc.,
Minneapolis, USA). The MAT1A gene was character-
ized by amplifying the coding regions of exons I to IX
and the corresponding intron–exon junctions by PCR
using nine pairs of oligonucleotide primers containing
5¶-untranslated, 3¶-untranslated and intron sequences
of the MAT1A gene as previously described (Ubagai
et al 1995). All amplified fragments were sequenced
using an ABI Prism DNA sequencing kit (Perkin
Elmer, Waltham, MA, USA) and then processed on an
ABI Prism 310 genetic analyser (Perkin Elmer). The
sequences from all exons I to IX were examined to
identify the presence of mutations.
Anthropometric evaluation
Body weight, body length and head circumference
were measured and expressed as centiles with respect
to the reference population.
Evaluation of cognitive and psychomotor development
The McCarthy Scales of Children_s Abilities (MSCA)
were used for preschool-age children, and the Brunet-
Le´zine scale for the child aged 13 months at evalua-
tion. Cognitive and developmental quotients were
considered normal from 85.
Results
Since the extension of the Galician Neonatal Screening
Program for Metabolic Abnormalities in June 2000 by
the introduction of tandem mass spectrometry, 6 cases
of persistent hypermethioninaemia have been detected
(up to June 2007). Over this period, a total of 140 818
newborns have been screened, indicating that persis-
tent hypermethioninaemia has an incidence of 1 in
23 470 in our region.
The six babies reported upon here were full-term
and had normal birth weights, and their methionine
elevations persisted. One of them was confirmed to
have CbS deficiency by enzymatic studies in fibroblasts
and by genetic studies. The five remaining cases were
confirmed by molecular studies of theMAT1A gene as
MAT I/III deficiency, giving a frequency of one case in
28 163, similar to the results from Portugal reported
Table 1 Characteristics of the patients with MAT I/III deficiency
Patient Current age Sex Neonatal screening
(MS/MS)
Confirmation (plasma) Mutation MAT1A Nucleotide change
Age Meta Age Meta tHcya
1 2 y 10 m F 6 d 50 35 d 573 22.8 R264H 791 g/a
2 2 y 8 m M 3 d 100 1 m 15 d 189 8.9 R264H 791 g/a
3 2 y 7 m F 5 d 88 2 m 21 d 341 9.7 R264H 791 g/a
4 2 y 6 m M 3 d 147 2 m 13 d 331 12.4 R264H 791 g/a
5 1 y 4 m M 5 d 100 25 d 164 11.0 R264H 791 g/a
y, year; m, month; d, day.
a mmol/L.
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recently (Martins et al 2007), but a higher incidence
than that reported for other areas, such as Taiwan
(Chien et al 2005; Hwu 2004). However, for almost all
the infants reported from Taiwan the cut-off point for
methionine was 134 mmol/L, considerably higher than
the cut-off range, 48–56 mmol/L, used in our present
programme.
All five of our cases were heterozygous for the same
mutation in MAT1A, R264H (G>A at nucleotide
791). This mutation shows a dominant phenotype,
since the mutated subunit sequesters normal subunits
to form inactive dimers (Chamberlin et al 1997; Perez-
Mato et al 2001). Table 1 shows methionine levels in
neonatal screening samples taken within 3–6 days of
birth (the programme recommends sampling on day 3
of life). All patients initially presented with only
moderately elevated values (mean 97 mmol/L, range
50–147). Persistence of the isolated hypermethioninae-
mia was confirmed in subsequent plasma samples in
which the methionine levels were higher than at
detection but still only moderately elevated in 4 of
the 5 cases (patients 2, 3, 4 and 5) (mean 256 mmol/L,
range 164–341), with tHcy values within the normal
range (mean 10.5 mmol/L, range 8.9–12.4 mmol/L).
Only patient 1 showed more markedly elevated plasma
methionine (573 mmol/L), together with slightly ele-
vated tHcy (22.8 mmol/L). Interestingly, this was the
case with the lowest level of methionine at initial
diagnosis (50 mmol/L at 6 days of age). This was also
the first patient with persistent hypermethioninaemia
detected in our region_s neonatal screening
programme. However, mild elevations of plasma tHcy
are known to occur in MAT I/III deficiency (Ito et al
2003; Linnebank et al 2005; Stabler et al 2002).
Furthermore, in patient 1 the plasma values of
AdoMet and S-adenosylhomocysteine were not ele-
vated (128 and 32 mmol/L, respectively), and cysta-
thionine was somewhat above the reference range (575
nmol/L). These findings were supportive of MAT I/III
deficiency and against CbS deficiency. In the 4 patients
detected subsequently, these components were not
determined, but sequencing of their MAT1A genes
showed R264H mutations, indicating the presence of
MAT I/III deficiency and providing an explanation for
their hypermethioninaemia (Andria et al 2005; Mudd
et al 2003).
Plasma methionine was assayed in both parents of
five of the patients. In each family one of the parents
had an elevated concentration (Table 2), as expected
in view of the Mendelian dominance of R264H. The
father of patient 2 did not consent to an assay. In
addition, a new case of MAT I/III deficiency was
detected in a sister of patient 1, currently aged 7 years
(plasma methionine 124 mmol/L). This girl, who
likewise showed the R264H mutation, was born before
the expanded screening programme commenced. Four
of the parents who show hypermethioninaemia are
clinically well. The father of patient 4 has a cardiop-
athy not related to his hypermethioninaemia, and
shows moderately elevated levels of (hepatic) trans-
aminases, attributed to the pharmacological treatment
he receives.
All patients were prescribed free diets appropriate
for their ages without an excess of proteins but an
intake within the normal limits (FAO/WHO). Physical
development was normal in all patients, and none
showed clinical symptoms. Table 2 summarizes follow-
up of the patients studied, from confirmation of
diagnosis until the present, showing mean methionine
levels, number of determinations in each patient, and
minimum and maximum values recorded for each
patient. As can be seen, mean methionine levels were
in all cases below 300 mmol/L. Developmental quo-
tients (DQs) were not significantly correlated with
methionine levels at diagnosis and these quotients
remained within the normal range in all cases, though
Table 2 Follow-up and family study of the 5 cases
Patient Plasma methioninea DQ Family study (plasma Meta)
Mean (min–max) nb Father Mother
1 163.8 (43–585) 11 100 2 y 8 m 74 27 (N)
2 152.1 (84–247) 10 103 2 y 6 m n.a. 23 (N)
3 237.0 (149–364) 8 88 2 y 6 m 24 (N) 76
4 183.4 (58–330) 8 101 2 y 6 m 205 19 (N)
5 117.2 (49–173) 5 101 13 m 25 (N) 85
y, year; m, month;, (N) normal range; n.a., not assayed.
a mmol/L.
bNumber of determinations.
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patient 3 (with the highest mean methionine level at
regular monitoring) showed the lowest DQ (88, at the
lower limit of the normal range).
Discussion
Neonatal screening for hypermethioninaemia is not
easy, for diverse reasons. On the one hand, methionine
levels in blood are not always high enough for
detection of CbS deficiency during the first days of
life and, on the other hand, differential diagnosis may
be complicated, leading to a high number of requests
for repeat sampling in view of elevated methionine,
with consequent high economic and social costs in a
population-level screening programme. However, once
transient hypermethioninaemias due to use of milk
with high methionine content have been ruled out
(above all in premature newborns and other newborns
with low body weight (see ten Hoedt et al 2007)), it is
important to note that detection of cases of MAT I/III
deficiency can be achieved only by monitoring of
hypermethioninaemia, however moderate this may
be; patient 1 in the present study is a clear example
of this situation because she showed a blood methio-
nine level in the first sample of 50 mmol/L, very near to
the cut-off (Table 1).
Advances in knowledge of mutations in theMAT1A
gene have allowed non-aggressive diagnosis of both
the presence of MAT I/III deficiency and the extent of
the deficit in enzyme activity, removing any need for
hepatic biopsy (Chamberlin et al 1997, 2000; Kim et al
2002). The gradual worldwide spread of expanded
neonatal screening programmes (using MS/MS) will
lead to the detection of an increasing number of cases
of isolated persistent hypermethioninaemias due to
deficient MAT I/III activity. In the population consid-
ered in the present study, for example, diagnosis of the
sister of patient 1 was late, because methionine level
had not been determined in the neonatal period.
The most suitable management of individuals with
MAT I/III mutations has not been definitively estab-
lished, in part because relatively few patients are
known; in part because, having usually been detected
by newborn screening, these patients are still young;
and in part because the optimal treatment will
probably vary with the type of causative MAT1A
mutation(s). To date, among the very few individuals
known to have complete loss of MAT I/III activity
some have developed adverse clinical manifestations
(mental retardation; neurological disorders, especially
myelination defects; and body odour). The observed
neurotoxicity may perhaps be attributable to deficient
formation of AdoMet and, in a single reported case,
treatment with AdoMet was accompanied by reversal
of demyelination (Surtees et al 1991). In addition, high
levels of methionine (>1000 mmol/L) may inhibit
transport of other neutral amino acids into the brain,
with neurotoxic effects (Mudd et al 1995). However,
other individuals with no MAT I/III activity have
remained clinically normal (Hazelwood et al 1998;
Mudd et al 2001). Synthesis of AdoMet by MAT II,
encoded by a different gene, may sustain these
individuals. The known individuals with point muta-
tions in MAT1A and some residual, albeit far below
normal, MAT I/III activity have so far been clinically
normal. With respect to heterozygosity for the
MAT1A R264H mutation, it is encouraging that the
parents of our patients, including the father of patient
4 with a particularly high plasma methionine level (205
mmol/L), as well as other reported individuals with
raised plasma methionine due to such heterozygosity
have all been free of clinical difficulties attributable to
this mutation, even those who are elderly (Mudd et al
2001). Although there was clearly overlap in the
ranges, the plasma methionine values found in the
parents tended to be lower than those in their affected
children (Table 2). Similar tendencies are apparent in
the other families for which generational values have
been reported (Chamberlin et al 1997; Nagao and
Oyanagi 1997). The reasons for such a trend are not
established, but it may be dependent upon develop-
mental changes with ageing: plasma methionines
tended, on the whole, to decrease in the two R264
heterozygous children (Chamberlin et al 1997) for
whom age-dependent values were reported by Blom
and co-workers (Blom et al 1992); and Nagao and co-
workers found in three heterozygous children a mean
plasma methionine of 354 mmol/L (range 295–391
mmol/L) at age 0.1 years that had decreased to a mean
of 226 mmol/L (range 128–385 mmol/L) at ages 10–12
years. For the heterozygous parents of these children
the mean was 181 mmol/L (range 155–201 mmol/L) at
ages 26–28 years and 134mmol/L (range 111–148mmol/L)
at ages 37–40 years (Nagao and Oyanagi 1997).
None of our patients showed neurological symp-
toms, and thus none of them received treatment. Some
authors (Chien et al 2005) have limited dietary
methionine intake for patients with persistent isolated
hypermethioninaemia, maintaining plasma levels be-
low 150 mmol/L. However, there is concern that such
limitation may be counterproductive if it further
reduces synthesis of AdoMet in those with some
residual MAT I/III activity. At methionine levels
above 300 mmol/L, metabolites produced by transam-
ination may give rise to the offensive body odour seen
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in some patients, although there is no clear evidence
that this is otherwise harmful (Andria et al 2005; Gahl
et al 1988; Mudd et al 1995). We therefore consider
that strict limitation of dietary methionine intake is
unnecessary and indeed inadvisable. In our patient 1,
in view of the plasma methionine above 500 mmol/L
and the slightly elevated tHcy, we initially considered
use of a methionine-restricted diet. However, methio-
nine levels dropped to a mean of 164 mmol/L on a
normal diet, the presence of the R264H mutation was
established, and dietary treatment was not carried out.
The correlation between DQ and methionine levels
observed in patient 3 does not appear to be important,
but will be monitored in future follow-ups.
With respect to management of MAT I/III deficien-
cy, one note of caution may be mentioned: Recently, a
patient with a plasma methionine of 740 mmol/L and a
tHcy of 37 mmol/L was described who was suspected of
having CbS deficiency. During treatment that included
betaine administration, the methionine rose to 960–
1560 mmol/L and the patient developed brain oedema.
When it was realized that the correct diagnosis was
MAT I/III deficiency, the betaine was discontinued
and the brain oedema largely resolved (Tada et al
2004). There is evidence that extreme elevations of
methionine due to a variety of causes (perhaps
especially when accompanied by betaine administra-
tion) may lead to severe brain oedema (Braverman
et al 2005). This possibility should be borne in mind
when dealing with MAT I/III deficiency.
Conclusions
The incidence of MAT I/III deficiency in our popula-
tion is higher than has been reported in some previous
studies. It is worth noting that all of our patients
showed the same dominant mutation in MAT1A,
despite the fact that, to date, 27 mutations of this gene
have been published. Biochemical and clinical moni-
toring of these patients is important in case they need
S-adenosylmethionine supplementation, or, far less
likely, dietary restriction of methionine intake.
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